The Top 25 Broker Analyst Picks of the S&P 500
By The Online Investor Staff, updated Mon., Apr. 29, 2:27 AM
#22 of the S&P 500: Alexion Pharmaceuticals Inc. (ALXN) Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. Co. has developed and commercializes two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. Co. also has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency. Open the ALXN Page at The Online Investor »
Open the ALXN Page at The Online Investor (in a new window) »
|
April 29, 2024 2:27 AM Eastern
Hold (2.31 out of 4)
100th percentile
|
Hold (2.31 out of 4)
100th percentile
|
|